CervoMed Inc. (CRVO)
NASDAQ: CRVO · IEX Real-Time Price · USD
16.25
-0.33 (-1.99%)
At close: Jul 19, 2024, 4:00 PM
16.34
+0.09 (0.55%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
CervoMed Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CervoMed stock have an average target of 66, with a low estimate of 63 and a high estimate of 70. The average target predicts an increase of 306.15% from the current stock price of 16.25.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CervoMed stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy Initiates $63 | Strong Buy | Initiates | $63 | +287.69% | Jul 8, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +330.77% | May 29, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +300.00% | Apr 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +207.69% | Feb 15, 2024 |
Financial Forecast
Revenue This Year
8.81M
from 7.14M
Increased by 23.25%
Revenue Next Year
5.24M
from 8.81M
Decreased by -40.54%
EPS This Year
-1.71
from -0.82
EPS Next Year
-2.32
from -1.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.9M | 6.2M | n/a | n/a | 70.2M |
| Avg | 8.8M | 5.2M | n/a | n/a | 36.7M |
| Low | 8.0M | 4.4M | n/a | n/a | 4.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.1% | -29.7% | - | - | - |
| Avg | 23.2% | -40.5% | - | - | - |
| Low | 12.5% | -49.9% | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.41 | -1.70 | -2.10 | -3.93 | -12.18 |
| Avg | -1.71 | -2.32 | -3.04 | -3.81 | -11.83 |
| Low | -1.83 | -3.09 | -4.08 | -3.67 | -11.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.